Algert Global LLC Grows Position in Aveanna Healthcare Holdings Inc. $AVAH

Algert Global LLC grew its holdings in Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) by 120.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,022,599 shares of the company’s stock after buying an additional 557,898 shares during the period. Algert Global LLC owned 0.49% of Aveanna Healthcare worth $9,070,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. AustralianSuper Pty Ltd acquired a new stake in shares of Aveanna Healthcare in the 3rd quarter worth $15,743,000. Vanguard Group Inc. grew its stake in shares of Aveanna Healthcare by 34.7% in the 3rd quarter. Vanguard Group Inc. now owns 4,041,659 shares of the company’s stock valued at $35,850,000 after buying an additional 1,041,324 shares during the period. Hillsdale Investment Management Inc. purchased a new stake in shares of Aveanna Healthcare during the 3rd quarter valued at approximately $7,922,000. Assenagon Asset Management S.A. acquired a new position in Aveanna Healthcare in the third quarter valued at approximately $7,356,000. Finally, Arrowstreet Capital Limited Partnership grew its position in Aveanna Healthcare by 451.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 959,488 shares of the company’s stock worth $8,511,000 after acquiring an additional 785,452 shares during the period. 87.96% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Aveanna Healthcare news, CEO Jeff Shaner sold 173,225 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total transaction of $1,248,952.25. Following the completion of the transaction, the chief executive officer owned 2,650,892 shares in the company, valued at $19,112,931.32. The trade was a 6.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Patrick A. Cunningham sold 18,436 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $7.21, for a total transaction of $132,923.56. Following the completion of the sale, the insider directly owned 337,755 shares in the company, valued at approximately $2,435,213.55. This represents a 5.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 998,595 shares of company stock worth $7,567,770 over the last 90 days. 7.00% of the stock is owned by insiders.

Aveanna Healthcare Stock Performance

NASDAQ:AVAH opened at $6.87 on Tuesday. Aveanna Healthcare Holdings Inc. has a 52 week low of $3.73 and a 52 week high of $10.32. The company has a fifty day simple moving average of $8.00 and a two-hundred day simple moving average of $8.54. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 140.39. The company has a market cap of $1.44 billion, a price-to-earnings ratio of 19.08 and a beta of 2.07.

Wall Street Analysts Forecast Growth

AVAH has been the subject of several recent analyst reports. William Blair began coverage on Aveanna Healthcare in a research report on Monday, December 8th. They issued an “outperform” rating on the stock. Royal Bank Of Canada upped their target price on shares of Aveanna Healthcare from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Thursday, January 15th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Aveanna Healthcare in a research note on Monday, December 29th. Zacks Research downgraded shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. Finally, UBS Group lifted their target price on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the company a “neutral” rating in a report on Thursday, January 15th. Five equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Aveanna Healthcare presently has an average rating of “Hold” and a consensus price target of $11.06.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.